Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.

Impagnatiello F, Bastia E, Almirante N, Brambilla S, Duquesroix B, Kothe AC, Bergamini MVW.

Br J Pharmacol. 2019 Apr;176(8):1079-1089. doi: 10.1111/bph.14328. Epub 2018 May 24. Review.

PMID:
29669171
2.

New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.

Abid S, Kebe K, Houssaïni A, Tomberli F, Marcos E, Bizard E, Breau M, Parpaleix A, Tissot CM, Maitre B, Lipskaia L, Derumeaux G, Bastia E, Mekontso-Dessap A, Adnot S.

J Cardiovasc Pharmacol. 2018 May;71(5):283-292. doi: 10.1097/FJC.0000000000000570.

PMID:
29438213
3.

New furoxan derivatives for the treatment of ocular hypertension.

Blangetti M, Rolando B, Chegaev K, Guglielmo S, Lazzarato L, Durante M, Masini E, Almirante N, Bastia E, Impagnatiello F, Fruttero R, Gasco A.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):479-483. doi: 10.1016/j.bmcl.2016.12.041. Epub 2016 Dec 18.

4.

Repeated Dosing with NCX1404, a Nitric Oxide-Donating Pregabalin, Re-establishes Normal Nociceptive Responses in Mice with Streptozotocin-Induced Painful Diabetic Neuropathy.

Varani K, Vincenzi F, Targa M, Ravani A, Bastia E, Storoni L, Brambilla S, Almirante N, Impagnatiello F.

J Pharmacol Exp Ther. 2016 May;357(2):240-7. doi: 10.1124/jpet.115.230193. Epub 2016 Feb 23.

PMID:
26907623
5.

Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.

Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AH.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6558-64. doi: 10.1167/iovs.15-17190.

PMID:
26457541
6.

Nitric oxide (NO): an emerging target for the treatment of glaucoma.

Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E.

Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15. doi: 10.1167/iovs.14-14515. Review.

PMID:
25125670
7.

The nitric oxide donating triamcinolone acetonide NCX 434 does not increase intraocular pressure and reduces endothelin-1 induced biochemical and functional changes in the rabbit eye.

Impagnatiello F, Giambene B, Lanzi C, Pini A, Somma T, Bastia E, Ongini E, Galassi F, Masini E.

Br J Ophthalmol. 2012 May;96(5):757-61. doi: 10.1136/bjophthalmol-2011-300404. Epub 2012 Jan 18.

PMID:
22257787
8.

A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.

Borghi V, Bastia E, Guzzetta M, Chiroli V, Toris CB, Batugo MR, Carreiro ST, Chong WK, Gale DC, Kucera DJ, Jia L, Prasanna G, Ongini E, Krauss AH, Impagnatiello F.

J Ocul Pharmacol Ther. 2010 Apr;26(2):125-32. doi: 10.1089/jop.2009.0120.

PMID:
20415621
9.

Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.

Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA.

J Neurosci. 2006 Dec 27;26(52):13548-55.

10.

Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice.

Benn SC, Ay I, Bastia E, Chian RJ, Celia SA, Pepinsky RB, Fishman PS, Brown RH Jr, Francis JW.

J Neurochem. 2005 Nov;95(4):1118-31.

11.

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.

Xu K, Bastia E, Schwarzschild M.

Pharmacol Ther. 2005 Mar;105(3):267-310. Epub 2004 Dec 21. Review.

PMID:
15737407
12.

A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization.

Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA.

Neuropsychopharmacology. 2005 May;30(5):891-900.

13.

Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS.

Francis JW, Bastia E, Matthews CC, Parks DA, Schwarzschild MA, Brown RH Jr, Fishman PS.

Brain Res. 2004 Jun 11;1011(1):7-13.

PMID:
15140640
14.

Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.

Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG.

Mol Pharmacol. 2004 Jan;65(1):121-9.

PMID:
14722243
15.

Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.

Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA.

Neurology. 2003 Dec 9;61(11 Suppl 6):S74-81.

PMID:
14663016
16.

Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization.

Chen JF, Moratalla R, Yu L, Martín AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA.

Neuropsychopharmacology. 2003 Jun;28(6):1086-95. Epub 2003 Apr 9.

17.

DARPP chocolate: a caffeinated morsel of striatal signaling.

Bastia E, Schwarzschild MA.

Sci STKE. 2003 Jan 14;2003(165):PE2. Review.

PMID:
12527819
18.

Lack of the nociceptin receptor does not affect acute or chronic nociception in mice.

Bertorelli R, Bastia E, Citterio F, Corradini L, Forlani A, Ongini E.

Peptides. 2002 Sep;23(9):1589-96.

PMID:
12217419
19.

Effects of A(1) and A(2A) adenosine receptor ligands in mouse acute models of pain.

Bastia E, Varani K, Monopoli A, Bertorelli R.

Neurosci Lett. 2002 Aug 16;328(3):241-4.

PMID:
12147316
20.

Atrial ejection force in patients with atrial fibrillation: comparison between DC shock and pharmacological cardioversion.

Mattioli AV, Castelli A, Bastia E, Mattioli G.

Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 1):33-8.

PMID:
9990598
21.

Doppler echocardiographic findings in patients with right ventricular infarction.

Mattioli AV, Bastia E, Mattioli G.

J Ultrasound Med. 1998 May;17(5):297-301.

PMID:
9586701
22.

Supplemental Content

Loading ...
Support Center